Erdafitinib + cetrelimab for carcinoma, transitional cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Mar 2018: Trial registered, NCT03473743
  2. 5 Apr 2018: Trial started, NCT03473743

The trials

NCT03473743: A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

State
Under way
Phase
Phase 1 and Phase 2
People
125 taking part
Started
5 Apr 2018
Primary completion
30 Sep 2022
Arms
Phase 2: Dose Expansion
Results
Posted on the registry
  1. 22 Mar 2018: Trial registered
  2. 5 Apr 2018: Trial started
  3. 25 Oct 2023: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.